

Please add the following new claims. These claims correspond to claims 68-70, 72, 74(partially), and 75(partially) as originally filed.

Sub  
Ch  
B  
118.(new) The isolated nucleic acid molecule of claim 67, wherein the sequence of contiguous nucleotides is selected from the group consisting of:

- (1) at least two contiguous nucleotides nonidentical to the sequence group,
- (2) at least three contiguous nucleotides nonidentical to the sequence group,
- (3) at least four contiguous nucleotides nonidentical to the sequence group,
- (4) at least five contiguous nucleotides nonidentical to the sequence group,
- (5) at least six contiguous nucleotides nonidentical to the sequence group,
- (6) at least seven contiguous nucleotides nonidentical to the sequence group.

B<sup>n</sup>  
119.(new) The isolated nucleic acid molecule of claim 67, wherein the fragment has a size selected from the group consisting of at least: 8 nucleotides, 10 nucleotides, 12 nucleotides, 14 nucleotides, 16 nucleotides, 18 nucleotides, 20, nucleotides, 22 nucleotides, 24 nucleotides, 26 nucleotides, 28 nucleotides, 30 nucleotides, 50 nucleotides, 75 nucleotides, 100 nucleotides, and 200 nucleotides.

120.(new) The isolated nucleic acid molecule of claim 67, wherein the molecule encodes a polypeptide which, or a fragment of which, binds a human HLA receptor or a human antibody.

Sub  
Ch  
121.(new) An expression vector comprising a nucleic acid operably linked to a promoter, wherein the nucleic acid is a NA Group 2 molecule.

122.(new) A host cell transformed or transfected with an expression vector of claims 121.

123.(new) A host cell transformed or transfected with an expression vector of claim 121 and further comprising a nucleic acid encoding HLA.


-3-

**Remarks**

Applicants have amended claim 71 and added new claims 118-123. Applicants also canceled a number of claims. The number of claims that will be pending after this amendment does not exceed the number previously paid for, and therefore no additional claims fees are due.

Support for the amendment to claim 71 and the new claims can be found in the claims as originally filed. No new matter has been added.

Respectfully submitted,

  
John R. Van Amsterdam, Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
Federal Reserve Plaza  
600 Atlantic Avenue  
Boston, Massachusetts 02210  
Tel.: (617) 720-3500

Docket No.: L0461/7078  
Date: November 30, 2000  
X12/03/01

578829\_1

Nov 30 2001 15:33 P.10

Fax:6177202441

WOLF GREENFIELD

**Amended Claim**

71.(twice amended) An expression vector comprising an isolated nucleic acid molecule of claim [59] 67 operably linked to a promoter.

578829\_1

Nov 30 2001 15:33 P.11

Fax:6177202441

WOLF GREENFIELD